Who made semaglutide, and how did it become a weight-loss medicine?

Which company invented semaglutide, and when?

Novo Nordisk (headquartered in Bagsværd, Denmark) developed semaglutide. The company has been researching insulin and metabolic hormones since the 1920s, and semaglutide grew directly out of that lineage. Scientists at Novo Nordisk spent years studying GLP-1 (glucagon-like peptide-1), a hormone the small intestine releases after a meal. GLP-1 tells the pancreas to release insulin, slows gastric emptying, and signals to the brain that you have eaten enough. The problem with natural GLP-1 is that the body breaks it down within minutes, making it useless as a medicine in its raw form.

The team's solution was to modify the molecule structurally, attaching a fatty-acid chain that allows it to bind to albumin in the bloodstream and survive for roughly a week. That single pharmacological innovation is why semaglutide can be injected once weekly rather than several times a day. The resulting compound was named semaglutide, entered clinical trials for type 2 diabetes, and received regulatory approval under the brand name Ozempic before the weight-management programme began. You can read more about how semaglutide is manufactured for a closer look at the production process.

The STEP clinical programme, which generated the evidence behind Wegovy's weight-management licence, was also Novo Nordisk's work, and if you want to understand who made Wegovy and the story behind its development, that page covers the company's role in detail. STEP 1 (published in the New England Journal of Medicine) randomised over 1,900 adults and found around 15% average weight reduction at 2.4mg over 68 weeks. That body of evidence underpinned the UK licence for Wegovy.

Is semaglutide the same thing as Ozempic and Wegovy?

Yes, and this is where a lot of confusion lives. The active molecule in Ozempic, Wegovy, and the newer Wegovy tablets is the same: semaglutide. What differs is the licensed indication, the dose, and the formulation. Ozempic is licensed in the UK for type 2 diabetes only; its doses (up to 2mg weekly by injection) are set for blood-sugar management. Wegovy is licensed for weight management, at a higher 2.4mg weekly maintenance dose, and more recently up to 7.2mg, following MHRA approval in early 2026.

A common misconception is that Ozempic and Wegovy are interchangeable for weight loss. They are not interchangeable under UK law: prescribing Ozempic for weight management would be off-label, and the MHRA is clear that GLP-1 medicines should not be used for cosmetic or quick-fix weight loss outside their licensed indications. The NHS medicines page for semaglutide sets out this distinction plainly.

The Wegovy tablet, approved by the MHRA on 11 June 2026, was the first oral GLP-1 licensed for weight management in the UK. It is also made by Novo Nordisk and contains semaglutide co-formulated with an absorption enhancer so the molecule can survive the stomach. Same inventor, same molecule, new delivery route. If you want to explore what semaglutide is derived from, that page covers its molecular origins in more detail.

What does Novo Nordisk's involvement mean for the medicine's quality and supply?

Novo Nordisk is one of the largest pharmaceutical companies in the world by market capitalisation and supplies the vast majority of global GLP-1 medicines. Their manufacturing facilities are regulated to stringent international standards, and UK-supplied Wegovy is distributed through the licensed UK supply chain, meaning it has been authorised by the MHRA and arrives via regulated wholesalers, not grey-market routes.

This matters practically. The MHRA has warned repeatedly about counterfeit pens sold through social media and unregistered websites, some of which have contained insulin rather than semaglutide. Genuine Wegovy, prescribed through a GPhC-registered pharmacy sourcing from authorised suppliers, comes from Novo Nordisk's own production. There is no legitimate version of this medicine available without a prescription and clinical assessment. You can verify any online pharmacy on the GPhC register before you hand over personal or financial details.

For context on what treatment costs privately, the Wegovy pricing page explains how the UK private market is structured without hiding any numbers. And if you are curious whether semaglutide does more than reduce appetite, this page on metabolism summarises the current evidence. At nume, at nume, prescriptions are reviewed by a named GPhC-registered Independent Prescriber who reads your consultation personally, and medicine is sourced through Novo Nordisk's authorised UK supply chain. That connection back to the original manufacturer is not a detail worth skipping.

If you would like to find out whether semaglutide is clinically suitable for you, our prescribers can assess your situation the same day through a free consultation.